Display options
Share it on

Cancers (Basel). 2019 Oct 11;11(10). doi: 10.3390/cancers11101537.

PATZ1 Is Overexpressed in Pediatric Glial Tumors and Correlates with Worse Event-Free Survival in High-grade Gliomas.

Cancers

Annalisa Passariello, Maria Elena Errico, Vittoria Donofrio, Manuela Maestrini, Alia Zerbato, Laura Cerchia, Maria Capasso, Mario Capasso, Monica Fedele

Affiliations

  1. Department of Pediatric Oncology, Santobono-Pausilipon Hospital, 80123 Naples, Italy. [email protected].
  2. Department of Translational Medical Science Pediatric Section, University of Naples Federico II, 80131 Naples, Italy. [email protected].
  3. Pathology Unit, Santobono-Pausilipon Hospital, 80123 Naples, Italy. [email protected].
  4. Pathology Unit, Santobono-Pausilipon Hospital, 80123 Naples, Italy. [email protected].
  5. Department of Translational Medical Science Pediatric Section, University of Naples Federico II, 80131 Naples, Italy. [email protected].
  6. Department of Translational Medical Science Pediatric Section, University of Naples Federico II, 80131 Naples, Italy. [email protected].
  7. National Research Council (CNR), Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), 80145 Naples, Italy. [email protected].
  8. Department of Pediatric Oncology, Santobono-Pausilipon Hospital, 80123 Naples, Italy. [email protected].
  9. CEINGE Biotecnologie avanzate, 80145 Naples, Italy. [email protected].
  10. Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy. [email protected].
  11. National Research Council (CNR), Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), 80145 Naples, Italy. [email protected].

PMID: 31614588 PMCID: PMC6826955 DOI: 10.3390/cancers11101537

Abstract

Glial tumors are the leading cause of cancer-related death and morbidity in children. Their diagnosis, mainly based on clinical and histopathological factors, is particularly challenging because of their high molecular heterogeneity. Thus, tumors with identical histotypes could result in variable biological behaviors and prognoses. The PATZ1 gene has been recently shown to be expressed in adult gliomas, including glioblastomas, where it correlates with the proneural subtype and with a better prognosis. Here, we analyzed the expression of PATZ1 in pediatric gliomas, first at mRNA level in a public database, and then at protein level, by immunohistochemistry, in a cohort of 52 glial brain tumors from young patients aged from 6 months to 16 years. As for adult tumors, we show that PATZ1 is enriched in glial tumors compared to the normal brain, where it correlates positively and negatively with a proneural and mesenchymal signature, respectively. Moreover, we show that PATZ1 is expressed at variable levels in our cohort of tumors. Higher expression was detected in high-grade than low-grade gliomas, suggesting a correlation with the malignancy. Among high-grade gliomas, higher levels of PATZ1 have consistently been found to correlate with worse event-free survival. Therefore, our study may imply new diagnostic opportunities for pediatric gliomas.

Keywords: PATZ1; glioma; pediatric brain tumors; prognosis

References

  1. NPJ Precis Oncol. 2017 Mar 20;1(1):5 - PubMed
  2. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  3. Oncotarget. 2017 Jul 25;8(35):59282-59300 - PubMed
  4. Int J Mol Sci. 2019 Jun 04;20(11):null - PubMed
  5. Int J Mol Sci. 2017 Nov 24;18(12): - PubMed
  6. Curr Treat Options Oncol. 2018 Jun 21;19(8):41 - PubMed
  7. Pediatr Blood Cancer. 2013 Dec;60(12):2031-5 - PubMed
  8. Pediatr Blood Cancer. 2016 Oct;63(10):1806-13 - PubMed
  9. Oncologist. 2017 Dec;22(12):1478-1490 - PubMed
  10. Oncol Rep. 2017 Dec;38(6):3685-3692 - PubMed
  11. J Immunol. 2013 Nov 1;191(9):4880-8 - PubMed
  12. Sci Rep. 2014 Dec 17;4:7519 - PubMed
  13. Brain Pathol. 2019 Jan;29(1):53-62 - PubMed
  14. J Clin Oncol. 2010 Jun 20;28(18):3061-8 - PubMed
  15. Oncotarget. 2016 Aug 9;7(32):52255-52269 - PubMed
  16. Brief Funct Genomic Proteomic. 2007 Mar;6(1):8-18 - PubMed
  17. Front Oncol. 2013 Feb 28;3:28 - PubMed
  18. Cell Death Dis. 2013 Dec 12;4:e963 - PubMed
  19. Cancer Ther. 2008;6(B):865-876 - PubMed
  20. Oncologist. 2014 Apr;19(4):403-13 - PubMed
  21. Neurol Clin. 2018 Aug;36(3):533-556 - PubMed
  22. J Clin Invest. 2017 Feb 1;127(2):415-426 - PubMed
  23. Oncotarget. 2016 Sep 13;7(37):59158-59172 - PubMed
  24. Childs Nerv Syst. 2019 Dec;35(12):2355-2362 - PubMed
  25. Oncol Lett. 2016 Jul;12(1):73-78 - PubMed
  26. Med Sci Monit. 2018 Jun 21;24:4262-4270 - PubMed
  27. Eur J Cancer. 2017 Aug;81:206-225 - PubMed
  28. Cell Mol Life Sci. 2018 Mar;75(5):871-887 - PubMed
  29. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  30. J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273 - PubMed
  31. Neuro Oncol. 2011 Mar;13(3):317-23 - PubMed
  32. Oncotarget. 2015 Mar 10;6(7):5310-23 - PubMed
  33. Neuro Oncol. 2017 Feb 1;19(2):153-161 - PubMed

Publication Types